3
ESMO-MCBS v1.1
Scorecard version: 1
Indication details
- Tumour Type
- Thoracic Malignancies
- Tumour Sub-type
- Non-small-cell Lung Cancer
- Tumour Sub-Group
- EGFR+
- Control Arm
- Gefitinib
- Treatment Setting
- 1st line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer
- Trial Name
- ARCHER 1050
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- OS
- Form(s)
- Form 2a
Outcome Data
- PFS Control
- 9.2 months
- PFS Gain
- 5.5 months
- PFS HR
- 0.59 (0.47–0.74)
- OS Control
- 26.8
- OS Gain
- 7.3 months
- OS HR
- 0.76 (0.58–0.99)
- QoL Comment
- No improvement
- Toxicity Comment
- Increased toxicity
Final Score (after adjustments)
- Preliminary non-curative score
- 3
- Final non-curative Score
- 3
- Issue date
- 04.12.2019
- Release date
- 04.12.2019
DFS, disease-free survival; DoR, duration of response; EFS, event-free survival; HR, hazard ratio; iDFS, invasive disease-free survival; ITT, intention to treat; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; pCR, pathologic complete response/remission; PFS, progression-free survival; QoL, quality of life; RFS, relapse-free survival; RR, response rate